Application and challenges in using LC-MS assays for absolute quantitative analysis of therapeutic proteins in drug discovery

Bioanalysis

Volumn 6, Issue 6, 2014, Pages 859-879

  Zheng, Joanna ^a   Mehl, John ^a   Zhu, Yongxin ^a   Xin, Baomin ^a   Olah, Timothy ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAVALINTIDE; DRUG METABOLITE; MONOCLONAL ANTIBODY; PROTEIN;

DERIVATIZATION; DRUG CLEARANCE; DRUG RESEARCH; ENZYME LINKED IMMUNOSORBENT ASSAY; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; PRECIPITATION; QUANTITATIVE ANALYSIS; RECEPTOR BINDING ASSAY; REVIEW; SENSITIVITY AND SPECIFICITY; SOLID PHASE EXTRACTION; DRUG DEVELOPMENT; HUMAN; PROCEDURES;

CHROMATOGRAPHY, LIQUID; DRUG DISCOVERY; HUMANS; MASS SPECTROMETRY; PROTEINS;

EID: 84898749621     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.14.36     Document Type: Review

References (99)

1. Dimitrov DS. Therapeutic proteins. Methods Mol. Biol. 899, 1-26 (2012).
2. Li F, Fast D, Michael S. Absolute quantitation of protein therapeutics in biological matrices by enzymatic digestion and LC-MS. Bioanalysis 3(21), 2459-2480 (2011).
3. Kuang B, King L, Wang HF. Therapeutic monoclonal antibody concentration monitoring: free or total? Bioanalysis 2(6), 1125-1140 (2010).
4. Dubois M, Fenaille F, Clement G et al. Immunopurification and mass spectrometric quantification of the active form of a chimeric therapeutic antibody in human serum. Anal. Chem. 80(5), 1737-1745 (2008).
5. Rauh M. LC-MS/MS for protein and peptide quantification in clinical chemistry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 884, 59-67 (2012).
6. Wang Y, Qu Y, Bellows CL, Ahn JS, Burkey JL, Taylor SW. Simultaneous quantification of davalintide, a novel amylin-mimetic peptide, and its active metabolite in beagle and rat plasma by online SPE and LC-MS/MS. Bioanalysis 4(17), 2141-2152 (2012).
7. Ezan E, Bitsch F. Critical comparison of MS and immunoassays for the bioanalysis of therapeutic antibodies. Bioanalysis 1(8), 1375-1388 (2009).
8. Hoofnagle AN, Wener MH. The fundamental flaws of immunoassays and potential solutions using tandem mass spectrometry. J. Immunol. Methods 347(1-2), 3-11 (2009).
9. Smith HW, Butterfield A, Sun D. Detection of antibodies against therapeutic proteins in the presence of residual therapeutic protein using a solid-phase extraction with acid dissociation (SPEAD) sample treatment prior to ELISA. Regul. Toxicol. Pharmacol. 49(3), 230-237 (2007).
10. Wang YM, Fang L, Zhou L, Wang J, Ahn HY. A survey of applications of biological products for drug interference of immunogenicity assays. Pharm. Res. 29(12), 3384-3392 (2012).
11. Hart MH, de Vrieze H, Wouters D et al. Differential effect of drug interference in immunogenicity assays. J. Immunol. Methods 372(1-2), 196-203 (2011).
12. Wang SJ, Wu ST, Gokemeijer J et al. Attribution of the discrepancy between ELISA and LC-MS/MS assay results of a PEGylated scaffold protein in post-dose monkey plasma samples due to the presence of anti-drug antibodies. Anal. Bioanal. Chem. 402(3), 1229-1239 (2012).
13. Yang Z, Hayes M, Fang X, Daley MP, Ettenberg S, Tse FL. LC-MS/MS approach for quantification of therapeutic proteins in plasma using a protein internal standard and 2D-solid-phase extraction cleanup. Anal. Chem. 79(24), 9294-9301 (2007).
14. Heudi O, Barteau S, Zimmer D et al. Towards absolute quantification of therapeutic monoclonal antibody in serum by LC-MS/MS using isotope-labeled antibody standard and protein cleavage isotope dilution mass spectrometry. Anal. Chem. 80(11), 4200-4207 (2008).
15. Ji QC, Rodila R, El-Shourbagy TA. A sample preparation process for LC-MS/MS analysis of total protein drug concentrations in monkey plasma samples with antibody. J. Chromatogr. B 847(2), 133-141 (2007).
16. Ji QC, Rodila R, Gage EM, El-Shourbagy TA. A strategy of plasma protein quantitation by selective reaction monitoring of an intact protein. Anal. Chem. 75(24), 7008-7014 (2003).
17. Becher F, Pruvost A, Clement G, Tabet JC, Ezan E. Quantification of small therapeutic proteins in plasma by liquid chromatography-tandem mass spectrometry: application to an elastase inhibitor EPI-hNE4. Anal. Chem. 78(7), 2306-2313 (2006).
18. Yang Z, Ke J, Hayes M, Bryant M, Tse FL. A sensitive and high-throughput LC-MS/MS method for the quantification of PEGylated- interferon-alpha2a in human serum using monolithic C18 solid phase extraction for enrichment. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 877(18-19), 1737-1742 (2009).
19. Hagman C, Ricke D, Ewert S, Bek S, Falchetto R, Bitsch F. Absolute quantification of monoclonal antibodies in biofluids by liquid chromatography-tandem mass spectrometry. Anal. Chem. 80(4), 1290-1296 (2008).
20. Ewles M, Goodwin L. Bioanalytical approaches to analyzing peptides and proteins by LC-MS/MS. Bioanalysis 3(12), 1379-1397 (2011).
21. Mesmin C, Fenaille F, Ezan E, Becher F. MS-based approaches for studying the pharmacokinetics of protein drugs. Bioanalysis 3(5), 477-480 (2011).
22. Nowatzke WL, Rogers K, Wells E, Bowsher RR, Ray C, Unger S. Unique challenges of providing bioanalytical support for biological therapeutic pharmacokinetic programs. Bioanalysis 3(5), 509-521 (2011).
23. van de Merbel NC, Bronsema KJ, Nemansky M. Protein quantification using LC-MS: can it make a difference? Bioanalysis 4(17), 2113-2116 (2012).
24. van den Broek I, Niessen WM, van Dongen WD. Bioanalytical LC-MS/MS of protein-based biopharmaceuticals. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 929, 161-179 (2013).
25. Bischoff R, Bronsema KJ, van de Merbel NC. Analysis of biopharmaceutical proteins in biological matrices by LC-MS/MS I. Sample preparation. Trends Analyt. Chem. 48(0), 41-51 (2013).
26. Hopfgartner G, Lesur A, Varesio E. Analysis of biopharmaceutical proteins in biological matrices by LC-MS/MS II. LC-MS/MS analysis. Trends Analyt. Chem. 48(0), 52-61 (2013).
27. van den Broek I, Sparidans RW, Schellens JH, Beijnen JH. Quantitative bioanalysis of peptides by liquid chromatography coupled to (tandem) mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 872(1-2), 1-22 (2008).
28. Stejskal K, Potesil D, Zdrahal Z. Suppression of peptide sample losses in autosampler vials. J. Proteome Res. 12(6), 3057-3062 (2013).
29. van Midwoud PM, Rieux L, Bischoff R, Verpoorte E, Niederlander HA. Improvement of recovery and repeatability in liquid chromatography-mass spectrometry analysis of peptides. J. Proteome Res. 6(2), 781-791 (2007).
30. Xu Y, Mehl JT, Bakhtiar R, Woolf EJ. Immunoaffinity purification using anti-PEG antibody followed by two-dimensional liquid chromatography-tandem mass spectrometry for the quantification of a PEGylated therapeutic peptide in human plasma. Anal. Chem. 82(16), 6877-6886 (2010).
31. Zhang H, Xin B, Caporuscio C, Olah TV. Bioanalytical strategies for developing highly sensitive liquid chromatography-tandem mass spectrometry based methods for the peptide GLP-1 agonists in support of discovery PK/PD studies. Rapid Commun. Mass Spectrom. 25(22), 3427-3435 (2011).
32. Reubsaet JL, Beijnen JH, Bult A, van Maanen RJ, Marchal JA, Underberg WJ. Analytical techniques used to study the degradation of proteins and peptides: chemical instability. J. Pharm. Biomed. Anal. 17(6-7), 955-978 (1998).
33. Wolf R, Rosche F, Hoffmann T, Demuth HU. Immunoprecipitation and liquid chromatographic-mass spectrometric determination of the peptide glucose-dependent insulinotropic polypeptides GIP1-42 and GIP3-42 from human plasma samples. New sensitive method to analyze physiological concentrations of peptide hormones. J. Chromatogr. A 926(1), 21-27 (2001).
34. Fanciulli G, Azara E, Wood TD, Delitala G, Marchetti M. Liquid chromatography-mass spectrometry assay for quantification of gluten exorphin B5 in cerebrospinal fluid. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 852(1-2), 485-490 (2007).
35. Wu ST, Ouyang Z, Olah TV, Jemal M. A strategy for liquid chromatography-tandem mass spectrometry based quantitation of PEGylated protein drugs in plasma using plasma protein precipitation with water-miscible organic solvents and subsequent trypsin digestion to generate surrogate peptides for detection. Rapid Commun. Mass Spectrom. 25(2), 281-290 (2011).
36. Olah T, Ranasinghe A, Zhang H et al. The development and implementation of LC-MS-based bioanalytical methods for the quantification of protein therapeutics in drug discovery. In:Characterization of Protein Therapeutics Using Mass Spectrometry. Chen G (Ed.). Springer, NY, USA, 95-115 (2013).
37. Barr JR, Maggio VL, Patterson DG Jr et al. Isotope dilution-mass spectrometric quantification of specific proteins: model application with apolipoprotein A-I. Clin. Chem. 42(10), 1676-1682 (1996).
38. Russell WK, Park ZY, Russell DH. Proteolysis in mixed organic-aqueous solvent systems: applications for peptide mass mapping using mass spectrometry. Anal. Chem. 73(11), 2682-2685 (2001).
39. Norrgran J, Williams TL, Woolfitt AR, Solano MI, Pirkle JL, Barr JR. Optimization of digestion parameters for protein quantification. Anal. Biochem. 393(1), 48-55 (2009).
40. Proc JL, Kuzyk MA, Hardie DB et al. A quantitative study of the effects of chaotropic agents, surfactants, and solvents on the digestion efficiency of human plasma proteins by trypsin. J. Proteome Res. 9(10), 5422-5437 (2010).
41. Havlis J, Thomas H, Sebela M, Shevchenko A. Fast-response proteomics by accelerated in-gel digestion of proteins. Anal. Chem. 75(6), 1300-1306 (2003).
42. Lesur A, Varesio E, Hopfgartner G. Accelerated tryptic digestion for the analysis of biopharmaceutical monoclonal antibodies in plasma by liquid chromatography with tandem mass spectrometric detection. J. Chromatogr. A 1217(1), 57-64 (2010).
43. Halquist MS, Karnes HT. Quantification of Alefacept, an immunosuppressive fusion protein in human plasma using a protein analogue internal standard, trypsin cleaved signature peptides and liquid chromatography-tandem mass spectrometry. J. Chromatogr. B 879(11-12), 789-798 (2011).
44. Lu Q, Zheng X, McIntosh T et al. Development of different analysis platforms with LC-MS for pharmacokinetic studies of protein drugs. Anal. Chem. 81(21), 8715-8723 (2009).
45. Kehler J, Akella N, Citerone D, Szapacs M. Application of DBS for the quantitative assessment of a protein biologic using on-card digestion LC-MS/MS or immunoassay. Bioanalysis 3(20), 2283-2290 (2011).
46. Liu H, Manuilov AV, Chumsae C, Babineau ML, Tarcsa E. Quantitation of a recombinant monoclonal antibody in monkey serum by liquid chromatography-mass spectrometry. Anal. Biochem. 414(1), 147-153 (2011).
47. van den Broek I, Sparidans RW, Schellens JHM, Beijnen JH. Enzymatic digestion as a tool for the LC-MS/MS quantification of large peptides in biological matrices: measurement of chymotryptic fragments from the HIV-1 fusion inhibitor enfuvirtide and its metabolite M-20 in human plasma. J. Chromatogr. B 854(1-2), 245-259 (2007).
48. Ye H, Hill J, Kauffman J, Gryniewicz C, Han X. Detection of protein modifications and counterfeit protein pharmaceuticals using isotope tags for relative and absolute quantification and matrix-assisted laser desorption/ionization tandem time-of-flight mass spectrometry: studies of insulins. Anal. Biochem. 379(2), 182-191 (2008).
49. Kuzyk MA, Smith D, Yang J et al. Multiple reaction monitoring-based, multiplexed, absolute quantitation of 45 proteins in human plasma. Mol. Cell. Proteomics 8(8), 1860-1877 (2009).
50. Hewavitharana AK, Herath HM, Shaw PN, Cabot PJ, Kebarle P. Effect of solvent and electrospray mass spectrometer parameters on the charge state distribution of peptides - a case study using liquid chromatography-mass spectrometry method development for beta-endorphin assay. Rapid Commun. Mass Spectrom. 24(24), 3510-3514 (2010).
51. Hahne H, Pachl F, Ruprecht B et al. DMSO enhances electrospray response, boosting sensitivity of proteomic experiments. Nat. Methods 10(10), 989-991 (2013).
52. Shipkova P, Drexler DM, Langish R, Smalley J, Salyan ME, Sanders M. Application of ion trap technology to liquid chromatography-mass spectrometry quantitation of large peptides. Rapid Commun. Mass Spectrom. 22(9), 1359-1366 (2008).
53. Sherwood CA, Eastham A, Lee LW, Risler J, Vitek O, Martin DB. Correlation between y-type ions observed in ion trap and triple quadrupole mass spectrometers. J. Proteome Res. 8(9), 4243-4251 (2009).
54. Paizs B, Suhai S. Fragmentation pathways of protonated peptides. Mass Spectrom. Rev. 24(4), 508-548 (2005).
55. Holstein CA, Gafken PR, Martin DB. Collision energy optimization of b- and y-ions for multiple reaction monitoring mass spectrometry. J. Proteome Res. 10(1), 231-240 (2010).
56. Neta P, Stein SE. Charge states of y ions in the collision-induced dissociation of doubly charged tryptic peptide ions. J. Am. Soc. Mass Spectrom. 22(5), 898-905 (2011).
57. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell. Proteomics 1(11), 845-867 (2002).
58. Ouyang Z, Furlong M, Wu S et al. Pellet digestion: a simple and efficient sample preparation technique for LC-MS/MS quantification of large therapeutic proteins in plasma. Bioanalysis 4(1), 17-28 (2012).
59. Yuan L, Arnold ME, Aubry AF, Ji QC. Simple and efficient digestion of a monoclonal antibody in serum using pellet digestion: comparison with traditional digestion methods in LC-MS/MS bioanalysis. Bioanalysis 4(24), 2887-2896 (2012).
60. Duan X, Young R, Straubinger RM et al. A straightforward and highly efficient precipitation/on-pellet digestion procedure coupled with a long gradient nano-LC separation and Orbitrap mass spectrometry for label-free expression profiling of the swine heart mitochondrial proteome. J. Proteome Res. 8(6), 2838-2850 (2009).
61. Inoue K, Ikemura A, Tsuruta Y et al. Quantification of N-acetyl-seryl-aspartyl-lysyl-proline in hemodialysis patients administered angiotensin-converting enzyme inhibitors by stable isotope dilution liquid chromatography-tandem mass spectrometry. J. Pharm. Biomed. Anal. 54(4), 765-771 (2011).
62. ten Have S, Boulon S, Ahmad Y, Lamond AI. Mass spectrometry-based immuno-precipitation proteomics - the user's guide. Proteomics 11(6), 1153-1159 (2011).
63. Ackermann BL, Berna MJ. Coupling immunoaffinity techniques with MS for quantitative analysis of low-abundance protein biomarkers. Expert Rev. Proteomics 4(2), 175-186 (2007).
64. Dubois M, Becher F, Herbet A, Ezan E. Immuno-mass spectrometry assay of EPI-HNE4, a recombinant protein inhibitor of human elastase. Rapid Commun. Mass Spectrom. 21(3), 352-358 (2007).
65. Palandra J, Finelli A, Zhu M, Masferrer J, Neubert H. Highly specific and sensitive measurements of human and monkey interleukin 21 using sequential protein and tryptic peptide immunoaffinity LC-MS/MS. Anal. Chem. 85(11), 5522-5529 (2013).
66. Huang L, Biolsi S, Bales KR, Kuchibhotla U. Impact of variable domain glycosylation on antibody clearance: an LC-MS characterization. Anal. Biochem. 349(2), 197-207 (2006).
67. Hall MP, Gegg C, Walker K et al. Ligand-binding mass spectrometry to study biotransformation of fusion protein drugs and guide immunoassay development: strategic approach and application to peptibodies targeting the thrombopoietin receptor. AAPS J. 12(4), 576-585 (2010).
68. Li H, Ortiz R, Tran L et al. General LC-MS/MS method approach to quantify therapeutic monoclonal antibodies using a common whole antibody internal standard with application to preclinical studies. Anal. Chem. 84(3), 1267-1273 (2012).
69. Li H, Ortiz R, Tran LT et al. Simultaneous analysis of multiple monoclonal antibody biotherapeutics by LC-MS/MS method in rat plasma following cassette-dosing. AAPS J. 15(2), 337-346 (2013).
70. Mirzaei H, Regnier F. Enhancing electrospray ionization efficiency of peptides by derivatization. Anal. Chem. 78(12), 4175-4183 (2006).
71. Ciccimaro E, Hanks SK, Yu KH, Blair IA. Absolute quantification of phosphorylation on the kinase activation loop of cellular focal adhesion kinase by stable isotope dilution liquid chromatography-mass spectrometry. Anal. Chem. 81(9), 3304-3313 (2009).
72. Brun V, Dupuis A, Adrait A et al. Isotope-labeled protein standards: toward absolute quantitative proteomics. Mol. Cell. Proteomics 6(12), 2139-2149 (2007).
73. Ocaña MF, Neubert H. An immunoaffinity liquid chromatography-tandem mass spectrometry assay for the quantitation of matrix metalloproteinase 9 in mouse serum. Anal. Biochem. 399(2), 202-210 (2010).
74. Barnidge DR, Hall GD, Stocker JL, Muddiman DC. Evaluation of a cleavable stable isotope labeled synthetic peptide for absolute protein quantification using LC-MS/MS. J. Proteome Res. 3(3), 658-661 (2004).
75. Bronsema KJ, Bischoff R, van de Merbel NC. Internal standards in the quantitative determination of protein biopharmaceuticals using liquid chromatography coupled to mass spectrometry. J. Chromatogr. B 893-894(0), 1-14 (2012).
76. Remily-Wood ER, Koomen JM. Evaluation of protein quantification using standard peptides containing single conservative amino acid replacements. J. Mass Spectrom. 47(2), 188-194 (2012).
77. Buscher BAP, Gerritsen H, van Schöll I, Cnubben NHP, Brüll LP. Quantitative analysis of Tenecteplase in rat plasma samples using LC-MS/MS as an alternative for ELISA. J. Chromatogr. B 852(1-2), 631-634 (2007).
78. Marshall AG, Hendrickson CL. High-resolution mass spectrometers. Annu. Rev. Anal. Chem. (Palo Alto Calif.) 1, 579-599 (2008).
79. Wei H, Tymiak AA, Chen G. High-resolution MS for structural characterization of protein therapeutics: advances and future directions. Bioanalysis 5(10), 1299-1313 (2013).
80. Wong RL, Xin B, Olah T. Optimization of Exactive Orbitrap™ acquisition parameters for quantitative bioanalysis. Bioanalysis 3(8), 863-871 (2011).
81. Dillen L, Cools W, Vereyken L et al. Comparison of triple quadrupole and high-resolution TOF-MS for quantification of peptides. Bioanalysis 4(5), 565-579 (2012).
82. Ranasinghe A, Ramanathan R, Jemal M, D'Arienzo CJ, Humphreys WG, Olah TV. Integrated quantitative and qualitative workflow for in vivo bioanalytical support in drug discovery using hybrid Q-TOF-MS. Bioanalysis 4(5), 511-528 (2012).
83. Zhu M, Ma L, Zhang D et al. Detection and characterization of metabolites in biological matrices using mass defect filtering of liquid chromatography/high resolution mass spectrometry data. Drug Metab. Dispos. 34(10), 1722-1733 (2006).
84. Plumb RS, Johnson KA, Rainville P et al. UPLC/MS(E); a new approach for generating molecular fragment information for biomarker structure elucidation. Rapid Commun. Mass Spectrom. 20(13), 1989-1994 (2006).
85. Zhang H, Zhang D, Ray K, Zhu M. Mass defect filter technique and its applications to drug metabolite identification by high- resolution mass spectrometry. J. Mass Spectrom. 44(7), 999-1016 (2009).
86. Ruan Q, Ji QC, Arnold ME, Humphreys WG, Zhu M. Strategy and its implications of protein bioanalysis utilizing high-resolution mass spectrometric detection of intact protein. Anal. Chem. 83(23), 8937-8944 (2011).
87. Ramagiri S, Garofolo F. Large molecule bioanalysis using Q-TOF without predigestion and its data processing challenges. Bioanalysis, 4(5), 529-540 (2012).
88. Plumb RS, Fujimoto G, Mather J et al. Comparison of the quantification of a therapeutic protein using nominal and accurate mass MS/MS. Bioanalysis 4(5), 605-615 (2012).
89. Duan X, Abuqayyas L, Dai L, Balthasar JP, Qu J. High-throughput method development for sensitive, accurate, and reproducible quantification of therapeutic monoclonal antibodies in tissues using orthogonal array optimization and nano liquid chromatography/selected reaction monitoring mass spectrometry. Anal. Chem. 84(10), 4373-4382 (2012).
90. Cao J, Gonzalez-Covarrubias V, Straubinger RM et al. A rapid, reproducible, on-the-fly orthogonal array optimization method for targeted protein quantification by LC-MS and its application for accurate and sensitive quantification of carbonyl reductases in human liver. Anal. Chem. 82(7), 2680-2689 (2010).
91. Gil J, Cabrales A, Reyes O et al. Development and validation of a bioanalytical LC-MS method for the quantification of GHRP-6 in human plasma. J. Pharm. Biomed. Anal. 60(0), 19-25 (2012).
92. Whiteaker JR, Zhao L, Anderson L, Paulovich AG. An automated and multiplexed method for high throughput peptide immunoaffinity enrichment and multiple reaction monitoring mass spectrometry-based quantification of protein biomarkers. Mol. Cell. Proteomics 9(1), 184-196 (2010).
93. Halfinger B, Sarg B, Amann A, Hammerer-Lercher A, Lindner HH. Unmasking low-abundance peptides from human blood plasma and serum samples by a simple and robust two-step precipitation/immunoaffinity enrichment method. Electrophoresis 32(13), 1706-1714 (2011).
94. Thomas A, Schanzer W, Delahaut P, Thevis M. Immunoaffinity purification of peptide hormones prior to liquid chromatography-mass spectrometry in doping controls. Methods 56(2), 230-235 (2012).
95. Huang EC, Henion JD. LC-MS and LC-MS/MS determination of protein tryptic digests. J. Am. Soc. Mass Spectrom.1(2), 158-165 (1990).
96. Duan X, Weinstock-Guttman B, Wang H et al. Ultrasensitive quantification of serum vitamin D metabolites using selective solid-phase extraction coupled to microflow liquid chromatography and isotope-dilution mass spectrometry. Anal. Chem. 82(6), 2488-2497 (2010).
97. Christianson CC, Johnson CJ, Needham SR. The advantages of microflow LC-MS/MS compared with conventional HPLC-MS/MS for the analysis of methotrexate from human plasma. Bioanalysis 5(11), 1387-1396 (2013).
98. Ramanathan R, Raghavan N, Comezoglu SN, Humphreys WG. A low flow ionization technique to integrate quantitative and qualitative small molecule bioanalysis. Int. J. Mass Spectrom. 301(1-3), 127-135 (2011).
99. Murphy RE, Kinhikar AG, Shields MJ et al. Combined use of immunoassay and two-dimensional liquid chromatography-mass spectrometry for the detection and identification of metabolites from biotherapeutic pharmacokinetic samples. J. Pharm. Biomed. Anal. 53(3), 221-227 (2010).